Essential thrombocythemia (ET) is a chronic myeloproliferative disorder characterized by elevated platelet levels in the blood, leading to thrombosis and an increased risk of thromboembolic complications. Due to increased platelet production, primary hemostatic mechanisms may be overactivated, leading to thrombus formation in various vessels, causing complications such as strokes and heart attacks. ET may be asymptomatic for a long time, but as the disease progresses, the patient may experience symptoms associated with increased blood viscosity, such as headaches, dizziness, weakness, and visual disturbances. The nature and etiology of ET are currently poorly understood, but it is known that the disease is more often found in older people and has a genetic predisposition.
History of the disease and interesting historical facts
Essential thrombocythemia was first described in the early 20th century. Pathological findings and clinical manifestations of the disease became known through the work of scientists such as H. O. Friedrich and R. W. Livingstone. In 1951, a common terminology was proposed for ET, which greatly simplified the diagnosis and understanding of the disease in the scientific community. In the following decades, the study of ET contributed to the discovery of many new molecular mechanisms and genetic abnormalities associated with this disease. In particular, the identification of the JAK2 V617F mutation in 2005 marked a new stage in the pathogenesis of ET. This discovery marked the contribution of molecular genetics to the diagnosis and treatment of not only ET, but also other myeloproliferative diseases.
Epidemiology
Essential thrombocythemia occurs in different populations with different frequencies. According to several epidemiological studies, the incidence of ET is about 2-5 cases per 100,000 people per year. However, this value may vary depending on geographic location and ethnicity. For example, some studies show that ET is more common in people of European descent, while the incidence is lower in Africans. The average age at diagnosis of ET is 60 years, with a higher incidence among women than men. The disease often develops gradually and remains undetected for a long time, making it difficult to estimate the true incidence.
Genetic predisposition to this disease
The study of the molecular genetic basis of essential thrombocythemia has identified several key mutations that play an important role in the pathogenesis of the disease. The most well-known is the mutation in the JAK2 gene, in particular the V617F mutation, which is found in approximately 50-60% patients with ET. In addition, other mutations such as CALR and MPL have also been associated with this disease, although they are less common. This genetic diversity makes the diagnosis more difficult and requires a thorough molecular genetic evaluation in clinical practice. Studies show that the presence of these mutations is associated with a different clinical picture and risk of thrombosis.
Risk factors for the development of this disease
There are various risk factors that may contribute to the development of essential thrombocythemia. These include:
- Age: The risk increases with age, especially after age 60.
- Gender: Women are more susceptible to ET than men.
- Family history: Having a family history of the disease may indicate a genetic predisposition.
- Chemical exposure: Long-term exposure to benzene and other carcinogens may increase the risk.
- Radiation treatment: Previous courses of radiation therapy may increase the risk of developing myeloproliferative disorders.
- Smoking: is considered a contributing factor to the development of ET.
Despite the presence of these factors, most patients with ET have no obvious predisposing factors, making the disease difficult to predict.
Diagnosis of this disease
Diagnosis of essential thrombocythemia includes several stages that allow establishing the correct diagnosis and assessing the patient's condition. The main symptoms that may indicate ET include:
- Headaches and dizziness.
- Changes in vision, including temporary blind spots.
- Redness of the skin, especially the face and palms.
- Bleeding (gums, nose) and bruising from minor injuries.
Laboratory studies include a complete blood count, which shows an elevated platelet count, and additional tests to identify mutations in the JAK2, CALR, and MPL genes. Radiologic studies, such as abdominal ultrasound, may be used to rule out splenomegaly and other associated complications. In addition, the differential diagnosis must include other myeloproliferative disorders and reactive thrombocytoses.
Treatment
Treatment for essential thrombocythemia varies and depends on individual patient characteristics, including age, underlying medical conditions, and platelet counts. General treatment principles include:
- Platelet count monitoring: maintain within acceptable range.
- Pharmacological treatment: use of Aspirin to reduce blood viscosity and prevent thrombus formation.
- Hydroxyurea: may be prescribed to reduce platelet production.
- Interferons: Used in some cases to control the disease.
- Surgical treatment: High-profile methods such as thrombocytophoresis can be used in acute situations.
- Innovative therapies: New drugs such as JAK inhibitors are also in the research phase.
Treatment should be individualized and carried out under constant medical supervision.
List of medications used to treat this disease
The main drugs used to treat essential thrombocythemia include:
- Aspirin
- Hydroxyurea
- Interferon alpha
- Ruxolitinib (JAK inhibitor)
- Thrombocytophoresis
- Sevelamer
The choice of a specific drug depends on the clinical situation and the patient's condition.
Disease monitoring
Monitoring of essential thrombocythemia includes regular control of platelet count, assessment of hemostasis, and detection of possible complications. The prognosis for patients with ET may vary: some patients may remain asymptomatic for a long time, while others experience severe thromboembolic complications. Complications such as strokes, heart attacks, and development of acute myeloid leukemia require active monitoring and adjustment of therapy. Successful monitoring includes regular consultations with a hematologist and laboratory monitoring at least once every 3-6 months.
Age-related features of the disease
Essential thrombocythemia can manifest itself differently depending on the patient's age. In young people, the disease can proceed more aggressively, with manifestations of thrombus formation, while in older people, ET is often observed without pronounced symptoms. In older people, comorbidities are often observed, which can complicate diagnosis and treatment. Also, ET is extremely rare in children and adolescents and requires a special approach to diagnosis and treatment. Age differences are important for understanding the course of the disease and approaches to therapy.
Questions and Answers
- What symptoms indicate possible essential thrombocythemia? The main symptoms include headaches, dizziness, visual disturbances, skin redness and nosebleeds.
- What are the main diagnostic methods for ET? Diagnostics include a complete blood count, molecular genetic tests for mutations in the JAK2, CALR and MPL genes, and radiological studies.
- What is the treatment for essential thrombocythemia? Treatment may include aspirin, hydroxyurea, interferons, and plateletpheresis in acute cases.
- Is there a risk of complications with essential thrombocythemia? Yes, serious complications such as stroke, myocardial infarction and development of acute myeloid leukemia are possible, which require constant monitoring.
- How often do I need to undergo follow-up examinations? It is recommended to have follow-up examinations every 3-6 months to monitor the status and level of platelets.
In conclusion, Dr. Oleg Korzhikov advises patients with essential thrombocythemia to pay closer attention to their health and not to ignore symptoms such as headaches and vision changes. He recommends avoiding stress and following a regimen. It is also important to undergo regular check-ups and choose treatment tactics based on recommendations from professionals to minimize the risk of thrombosis.
